Dariohealth corp. DRIO.US Overview
DRIO AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
DRIO Current Performance
-0.75%
Dariohealth corp.
0.98%
Avg of Sector
0.83%
S&P500
DRIO Key Information
DRIO Financial Forecast
Unit : USD
DRIO Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.06 | 70% | -14.3% | 6.75M | 17.3% | -13% | -126.7% |
| 2024Q3 | 0.01 | 102.4% | -106.3% | 7.6M | 110.3% | 0.4% | -166.1% |
| 2024Q2 | -0.13 | 73.5% | -27.8% | 7.42M | 111% | 0.2% | -217.6% |
| 2024Q1 | 0.06 | 110.3% | -120.7% | 6.26M | 1.7% | -20.9% | -124.6% |
| 2023Q4 | -0.2 | -144.4% | -66.1% | 5.76M | -18.5% | -14.8% | -395% |
DRIO Profile
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.